Key Takeaways DHR's Life Sciences segment's revenues are likely to drop 3.4% on weak demand in key end markets. Diagnostics performance is expected to be hurt by soft molecular test demand and lower China sales. Biotechnology revenues are projected to rise 7% on strong bioprocessing and discovery business demand.Danaher Corporation (DHR) is scheduled to release second-quarter 2025 results on July 22, before market open.The Zacks Consensus Estimate for revenues is pegged at $5.84 billion, which indicates a ...

Analysts on Wall Street project that Thermo Fisher Scientific (TMO) will announce quarterly earnings of $5.22 per share in its forthcoming report, representing a decline of 2.8% year over year. Revenues are projected to reach $10.65 billion, increasing 1% from the same quarter last year.The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial pro ...

Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was extreme."I think this is a little bit of an overreaction. Of course, we are all over this," Ford said. "We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact, and this is just really a point in time that we have to get through."While Abbott posted a top and bottom line beat for t ...

For the quarter ended June 2025, Abbott (ABT) reported revenue of $11.14 billion, up 7.4% over the same period last year. EPS came in at $1.26, compared to $1.14 in the year-ago quarter.The reported revenue represents a surprise of +0.63% over the Zacks Consensus Estimate of $11.07 billion. With the consensus EPS estimate being $1.25, the EPS surprise was +0.8%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations ...

Core Insights - Becton, Dickinson and Company (BDX) and Waters Corporation (WAT) have announced a strategic collaboration to merge BD's Biosciences Diagnostic Solutions business with Waters' analytical technologies expertise, creating a new entity focused on high-throughput testing in life sciences and diagnostics [1][9] Transaction Details - The merger has been unanimously approved by both companies' boards and is expected to close by the end of Q1 2026, pending regulatory and shareholder approvals [2] - BD will receive $4 billion in cash and hold a 39.2% stake in the new entity through a Reverse Morris Trust structure [8][12] Financial Projections - The combined company aims for $6.5 billion in revenues by 2025, with projections of reaching $9 billion and $3.3 billion in EBITDA by 2030 [8][11] - The total addressable market is expected to double to approximately $40 billion, allowing access to adjacent segments [10] Synergy and Growth Potential - The merger is projected to generate approximately $200 million in cost synergies by the third year post-closing and $290 million in revenue synergies by the fifth year [13] - Annualized EBITDA gains of about $345 million are anticipated by 2030, reinforcing the long-term value creation potential of the transaction [13] Market Position and Performance - BD currently has a market capitalization of $50.76 billion and an earnings yield of 8.1%, outperforming the industry average of 5.3% [5] - BDX shares have lost 21.9% year-to-date, contrasting with a 6.1% gain in the S&P 500 during the same period [3]

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 billion, representing an increase of 6.7% year over year.The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahea ...

Core Insights - Carbon-based clean technologies are expected to see only marginal growth, while renewable and clean energy technologies are projected to grow exponentially to meet rising global demand [1] - The Renewable Energy Market Review 2025 highlights emerging market dynamics, innovations, and strategies to navigate global uncertainty [2] Market Trends - The review discusses the next wave of renewable energy innovations and emphasizes that low carbon power generation extends beyond wind and solar [2] - The market is advancing data and analytics, integrating climate risk models, and enhancing risk management tools for renewable energy projects [3] - Increased insurance capacity is entering the market as insurers aim to capture growth in renewable energy, leading to softer pricing and broader terms [3] Challenges and Innovations - Softening market conditions are driven by an oversupply of capacity, intensifying competition among insurers and driving pricing downward [6] - Natural catastrophe losses from severe weather events pose significant challenges to assets [6] - Innovations in peril diagnostics and parametric solutions are evolving to help manage market volatility and uncertainty [6] - Emerging technologies such as kinetic infrastructure, solar-integrated materials, nuclear fusion, and gravity-based storage are gaining momentum in reshaping the energy landscape [6]

Company Overview - KLA Corporation is an original equipment manufacturer (OEM) specializing in process diagnostics and control (PDC) equipment and yield management solutions for semiconductor integrated circuits (ICs) fabrication [11] - The company offers a comprehensive portfolio addressing major PDC subsegments, including photomask inspection, wafer inspection/defect review, and metrology [11] Investment Ratings - KLA is rated 2 (Buy) on the Zacks Rank, indicating a positive outlook for the stock [12] - The company has a VGM Score of B, suggesting a balanced assessment of value, growth, and momentum [12] Performance Metrics - KLA's Momentum Style Score is A, reflecting strong recent performance with shares up 13% over the past four weeks [12] - In the last 60 days, 10 analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.89 to $32.46 per share [12] - KLA has an average earnings surprise of 5.8%, indicating a history of exceeding earnings expectations [12] Investment Considerations - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, KLA is recommended for investors' consideration [13]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Dev ...

Core Insights - Access Medical Labs has successfully transitioned from Siemens to Roche Diagnostics systems in under 6 months, a significant achievement in the clinical laboratory industry [1][4] - The integration has increased Access's daily diagnostic capacity fivefold, enabling faster and more comprehensive results for health providers nationwide [2] - The transition was facilitated by effective collaboration between Roche's U.S. and Mexico divisions, showcasing the benefits of international cooperation in medical innovation [4] Company Developments - The transformation is seen as a major step forward for the industry, with Access Medical Labs positioning itself as one of the most advanced diagnostic labs in the nation [4][5] - Access Medical Labs is expanding its workforce by 35% by the end of 2025, creating high-impact jobs in various sectors including lab science and logistics [6][7] - The company emphasizes its commitment to personalized medicine, aiming to make it more practical and accessible through innovative testing solutions [7] Industry Trends - There is a growing focus on preventive and personalized healthcare in the U.S., with Access Medical Labs supporting thousands of physicians in this area [5][6] - The nomination of Dr. Casey Means as U.S. surgeon general highlights the increasing national emphasis on proactive, data-driven medicine [6]